The FTC moves to block DNA sequencer Illumina’s acquisition of PacBio, calling company a ‘monopolist’
The FTC is challenging DNA sequencing giant Illumina’s proposed $1.2 billion purchase of rival Pacific Biosciences, alleging the acquisition would eliminate “a nascent competitive threat” to Illumina.
by Matthew Herper
Dec 17, 2019
2 minutes
The Federal Trade Commission is challenging DNA sequencing giant Illumina’s proposed $1.2 billion purchase of rival Pacific Biosciences, alleging the acquisition would eliminate “a nascent competitive threat” to Illumina’s monopoly in deciphering genetic material.
“When a monopolist buys a potential rival, it can harm competition,” the
You’re reading a preview, subscribe to read more.
Start your free 30 days